­
­
­
­

Inventi Impact: Molecular Pharmacology

Articles

  • Inventi:pmp/25565/18
    Matrine Ameliorates Colorectal Cancer in Rats via Inhibition of HMGB1 Signaling and\nDownregulation of IL-6, TNF-α, and HMGB1
    01-Jan-1970 Research 2018 : April - June
    Huizhen Fan, Chunyan Jiang, Baoyuan Zhong, Jianwen Sheng, Ting Chen, Qingqing Chen, Jingtao Li, Hongchuan Zhao

    Matrine may be protective against colorectal cancer (CRC), but how it may work is unclear. Thus, we explored the underlying\nmechanisms of matrine in CRC. Matrine-related proteins and CRC-related genes and therapeutic targets of matrine in CRC\nwere predicted using a network pharmacology approach. Five targets, including interleukin 6 (IL-6), the 26S proteasome, tumor\nnecrosis factor alpha (TNF-�±), transforming growth factor beta 1 (TGF-�²1) and p53, and corresponding high-mobility group\nbox 1 (HMGB1) signaling and T helper cell differentiation were thought to be associated with matrineâ��s mechanism. Expression\nof predicted serum targets were verified in a 1,2-dimethylhydrazine dihydrochloride-induced CRC model rats that were treated\nwith matrine (ip) for 18 weeks. Data show that matrine suppressed CRC growth and decreased previously elevated expression of\nIL-6, TNF-�±, p53, and HMGB1. Matrine may have had a therapeutic effect on CRC via inhibition of HMGB1 signaling, and this\noccurred through downregulation of IL-6, TNF-�±, and HMGB1.

    How to Cite this Article
    CC Compliant Citation: Huizhen Fan, Chunyan Jiang, Baoyuan\nZhong, et al., â??Matrine Ameliorates Colorectal Cancer in Rats via\nInhibition of HMGB1 Signaling and Downregulation of IL-6,\nTNF-α, and HMGB1,â? Journal of Immunology Research, vol.\n2018, Article ID 5408324, 8 pages, 2018.\ndoi:10.1155/2018/5408324, https://creativecommons.org/\nlicenses/by/4.0/.
    Download Full Text